A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Effect of Cynatine® FLX on Symptoms of Osteoarthritis

ABSTRACT

Objective: A novel product Cynatine® FLX was evaluated on symptoms associated with knee osteoarthritis in a randomized, double-blind, placebo-controlled clinical trial. Methods: A total of 50 males and females were included and randomized into two groups. The active group (n = 25) received two capsules totaling 500 mg of Cynatine® FLX per day and the placebo group (n = 25) received an identical two capsules of maltodextrin per day for 60 days. The WOMAC® Osteoarthritis Index, SF-36, and Lequesne Index of Severity were used to evaluate the symptoms. Results: The results show that Cynatine® FLX was twice as effective in reducing pain scores as compared to placebo. Cynatine® FLX showed the same effectiveness in reducing stiffness. Conclusion: This new product may be effective in relieving symptoms of knee osteoarthritis.

KEYWORDS. :

• Coxarthrosis
• Cynatine® FLX
• osteoarthritis
• SF-36
• VAS
• WOMAC